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Most sporadic colorectal cancers (CRCs) develop from preformed adenomas. Cytokines are 
involved in the transition from adenoma to CRC. Interleukin-33 (IL-33) is a newly discovered 
proinflammatory cytokine belonging to the IL-1 cytokine family and involved in the 
development of chronic inflammation and cancer. The aim of this study is to evaluate the 
dynamics of the IL-33/ST2 axis during the sequence of progression from normal colorectum 
to adenoma to carcinoma and to investigate the association of IL-33 and ST2 expression with 
clinicopathological parameters and prognosis. The results demonstrated that the levels of IL-
33 and ST2 in adenomas (n = 50), determined by real-time PCR, were significantly higher 
than those of normal controls (n = 30); the levels of both IL-33/ST mRNA in CRCs (n = 50) 
were higher than in normal controls but lower than levels in adenomas. Further analysis 
revealed that the expression level of ST2 in CRCs was associated with tumor/node/metastasis 
(TNM) stage. The log-rank test showed that neither the IL-33 nor the ST2 expression level 
was correlated with overall survival in patients with CRC. The increased expression of IL-
33/ST2 in adenomas and CRC tissues was confirmed by immunohistochemistry and was 
observed in both the tumor stromal cells and adenomatous/cancerous cells. Notably, increased 
densities of IL-33-positive and ST2-positive microvessels were found in the stroma of 
adenomas and CRCs. In conclusion, increased expression of the IL-33/ST2 axis along the 
colorectal adenoma-carcinoma sequence might be involved in the neoplastic transformation 
via the participation of this axis in the regulation of angiogenesis.  
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Précis 
The IL-33/ST2 axis changes along the adenoma-carcinoma progression sequence, particularly 
in the tumor stromal cells, microvessels and adenomatous/cancerous epithelium. An activated 






Human colorectal cancer (CRC) is the third most frequent cancer worldwide. According to 
the classic genetic model for colorectal tumorigenesis described by Fearon and Vogelstein [1], 
most sporadic CRCs develop primarily from a pre-existing principal precursor – an 
adenomatous polyp - through a progressive accumulation of a number of genetic mutations 
and molecular alterations [2, 3].  The transition from an adenoma to a sporadic CRC may take 
many years and invariably evokes a strong inflammatory response that includes inflammatory 
cell infiltration and pro-inflammatory cytokine secretion in the tumor microenvironment [4-
6]. Because these inflammatory components construct an inflammatory microenvironment 
and then contribute to the initiation and progression of CRC [7-12], it is important to 
investigate the dynamic temporal changes of this tumor inflammatory microenvironment. 
Indeed, we and others have previously demonstrated that the colorectal neoplastic 
transformation leads to remarkable changes in cytokine profiles in the tumor 
microenvironment [7, 9, 13, 14], which might have a significance in predicting the 
progression from  adenoma to CRC and the prognosis of the CRC [8, 10, 11, 13-16]. These 
findings provide new insights into transitional mechanisms of tumor progression and help to 
design novel interventional strategies. 
Interleukin (IL)-33 is a newly discovered pro-inflammatory cytokine belonging to the IL-1 
family. The IL-33/ST2 (IL-33 receptor) axis plays an important role in regulating both T 
helper (Th)1 and Th2 cell responses [17] and is involved in the pathogenesis of human 
inflammatory diseases [18, 19]. For colorectal diseases, extensive evidence now suggests that 
IL-33 is activated in the inflamed mucosa of ulcerative colitis and is known to be correlated 
with the development of chronic inflammation [18, 20]. Because the involvement of chronic 
inflammation, as seen in inflammatory bowel disease (IBD), has been suggested to be a 
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critical mechanism underlying CRC, the role of IL-33/ST2 in tumors has recently attracted 
much attention and investigation. Studies have shown that the IL-33/ST2 pathway plays an 
active role in inhibiting antitumor immunity and subsequently promoting metastasis in breast 
cancer [19, 21, 22]. In inflammation-associated pancreatic cancer, it might function as a 
crucial mediator that stimulates the process of carcinogenesis [23]. Moreover, two studies 
have shown that IL-33 is associated with tumor cell invasion or metastasis in head and neck 
squamous cell carcinoma [24] and hepatocellular carcinoma [25]. The prognostic significance 
of IL-33 has also been examined. Several reports have revealed that cancer patients with a 
high expression of IL-33 have a poor prognosis [24, 26, 27]. However, the involvement of IL-
33 in different human tumors is controversial; a protective role of IL-33 in some types of 
human cancers has also been reported. For example, a reduced IL-33 plasma level in patients 
with multiple myeloma is associated with a more advanced stage of disease [28].  
Despite extensive data describing the importance of IL-33/ST2 activation in the pathogenesis 
of chronic colorectal inflammation as seen in inflammatory bowel diseases [18, 20], the role 
of the IL-33/ST2 axis in the development of sporadic CRC has yet to be examined. It is 
known that the inflammatory response occurs throughout the adenoma-carcinoma sequence 
and contributes to the adenoma-cancer transition through the release of pro-tumor cytokines 
and other growth factors. In addition, we have previously found that the tumor 
microenvironment has a Th2 cytokine profile in the adenoma-carcinoma sequence [29].  
Moreover, it has been shown that IL-33 enhances Th2 polarization [17]. Given this, we 
hypothesized that an altered IL-33/ST2 axis might be involved in the pathogenesis of 
colorectal neoplastic transformation. In the present study, therefore, we characterized the 
dynamic changes of the IL-33/ST2 axis in the tumor microenvironment and evaluated its 
significance along the colorectal adenoma-carcinoma sequence. 
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Patients and Methods 
Patients 
Patients were enrolled at the Departments of Gastrointestinal Surgery and Gastroenterology at 
the University Hospital of North Norway: 50 colorectal adenomas excised completely by 
endoscopic polypectomy in patients ages 43-92 years, 50 CRC lesions excised by surgery in 
patients ages 42-89 years, and 30 morphologically normal colorectal mucosa samples 
confirmed by colonoscopic and histological examination in patients ages 24-79 years. Patients 
were recruited between August 2003 and December 2008 (for detailed information, refer to 
Table 1). None of the included patients or control subjects had a history of regular use of 
immunomodulation treatment or chemotherapy. All biopsies were prepared and routinely 
embedded in paraffin. Sections (4 m) were cut and stained with hematoxylin and eosin 
(H&E). Histological diagnosis of all biopsies was determined by experienced pathologists 
from the Department of Clinical Pathology at the University Hospital of North Norway and 
were reviewed by senior pathologist SWS. The study was approved by the Regional Ethical 
Committee of Northern Norway, and written informed consent was obtained from all patients.  
 
Real-time polymerase chain reaction (PCR) quantification of IL-33 and ST2 mRNA  
Biopsies were collected in RNAlater solution (Ambion Europe, Cambridgeshire, UK), total 
RNA was extracted by the TRIzol method (Invitrogen Life Tech., Carlsbad, CA, USA), and 
reverse transcription was performed with SuperScript II (Invitrogen Life Tech., Carlsbad, CA, 
USA). Real-time PCR was performed on an ABI-prism 7900 sequence detector with a 
TaqMan Gold™ PCR core reagents kit (Applied Biosystems/Roche, Branchburg, NJ, USA) 
in 25 L volume according to our previously published method [30]. The TaqMan primer 
sequences for the housekeeping gene (beta-actin) were: forward primer 5’ 
TGCCGACAGGATGCAGAAG 3’; reverse primer 5’ GCCGATCCACACGGAGTACT 3’; 
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and probe FAM 5’ AGATCAAGATCATTGCTCCTCCTGAGCGC 3’ TAMRA. Primer 
sequences for IL-33 were: forward primer 5’ TGAGTCTCAACACCCCTCAAATG 3’; 
reverse primer 5’ GGCATGCAACCAGAAGTCTTTT 3’; and probe FAM 5’ 
CAGGTGACGGTGTTGATGGTAAGATGTTAATG 3’ BHQ. IL-33 receptor ST2 primers 
were purchased from Life Technologies (Cat# No. 4331182; Grand Island, NY, USA).  The 
expression of IL-33 and ST2 mRNA in tissues obtained from the colorectal adenomas and 
CRCs was measured by cycle threshold (CT) value relative to that of the normal control 
mucosa as fold difference (N)=2
-ΔΔCT
, ΔCT = CT measured gene (IL-33 or ST2) - CT beta-actin, ΔΔCT= 
ΔCT adenoma or CRC - average ΔCT normal as described in our recent publication [14]. The 
difference among the normal control, colorectal adenoma and CRC were compared by ΔCT 
values.  
 
Immunohistochemical examinations of IL-33-positive cells and ST2-positive cells in the tumor 
microenvironment 
To evaluate the distribution and expression patterns of the IL-33/ST2 axis in the tumor 
microenvironment, immunohistochemistry (IHC) was performed using 4 m paraffin sections 
from the controls, adenomas and CRCs with a Vectastatin Elite ABC Kit (Vector Lab., 
Burlingame, CA, USA) according to the manufacturer’s instructions and our published 
methods [31]. The following primary antibodies were used: goat anti-human IL-33 polyclonal 
antibody (working dilution 1:100; R&D systems, Minneapolis, MN, USA) and mouse anti-
human ST2 monoclonal antibody (working dilution 1:100; Medical & Biological Laboratories 
Co. Ltd., Nagoya, Japan). Antibodies were incubated at 4ºC overnight. 3-Amino-9-
ethylcarbazole (AEC; Vector Laboratories, Burlingame, CA, USA) was used as chromogen, 
and slides were slightly counterstained with Mayer's hematoxylin. Negative control slides for 
IHC were used routinely as follows: (1) primary antibodies were substituted with the isotype-
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matched control antibodies; (2) secondary antibody was substituted with phosphate buffered 
saline (PBS).   
Evaluation of IL-33-expressing cell phenotypes in the tumor stroma by double IHC staining  
To define the phenotypes of IL-33-expressing cells in the tumor microenvironment, double 
IHC staining with the antibodies IL-33 (rabbit polyclonal antibody from Abcam, UK)/CD34 
(monoclonal antibody from Dako Cor., Carpinteria, CA, USA, to label microvessels), and IL-
33/SMA-alpha (monoclonal antibody from Dako Cor., Carpinteria, CA, USA, to label 
myofibroblasts) was performed using the EnVision Doublestain System kit (Dako Cor., 
Carpinteria, CA, USA) as previously described in our publication [14]. The 3-amino-9-
ethylcarbazole substrate kit for peroxidase (AEC, Vector Laboratories, Burlingame, CA, 
USA) was used for the visualization of IL-33 immunoreactivity, and the Vector Blue Alkaline 
Phosphatase Substrate Kit III (Vector Blue, Vector Laboratories, Burlingame, CA, USA) was 
used for CD34 and SMA-alpha immunoreactivity, respectively. Nuclear counterstaining was 
not applied.  
 
Morphometric analysis  
All stained slides were examined under light microscopy. IL-33-positive and ST2-positive 
cells were found to be present in both the lamina propria and the epithelium, and the densities 
of positive cells were evaluated in the lamina propria and epithelium according to the methods 
described in our previous publication [13]. In the stroma, semi-quantified scoring was 
performed in at least 3 optional fields with abundant distribution from each slide under 400 
high-power fields (HPF) and was scored as: nil (0), 1-19 cells/field (1+), 20-49 cells/field (2+) 
and over 50 cells/field (3+). IL-33-positive and ST2-positive microvessel densities (MVDs) in 
the stroma were quantified according to the previously published method [32]. In the 
epithelium, IL-33-positive cells and ST2-positive cells were graded on a scale of 0-3, with 0 
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representing no detectable staining and 3+ representing the strongest staining. The average 
values were used for statistical analysis.
 
 
Statistical analysis  
The results were expressed as the mean ± SEM (mean of standard error) unless otherwise 
stated. Statistical significance was evaluated by the Mann–Whitney test or the Kruskal–Wallis 
test. Kaplan–Meier analysis was used to calculate survival rates and differences in survival 
curves were determined by the log-rank test. The Cox proportional hazards regression model 
with a stepwise procedure was used to analyze the simultaneous influence of prognostic 
factors. Values of P < 0.05 and <0.01 were considered significant. 
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Results 
On the transcript level, the expression of the IL-33/ST2 axis was dynamically altered along 
the adenomas-carcinoma sequence  
The expression level of IL-33 mRNA in the adenoma tissues determined by real-time PCR 
was significantly increased compared to the normal controls (Fig. 1A). The expression of IL-
33 mRNA in the CRC tissues was also significantly higher than in the normal controls but 
lower than that in the adenomas (Fig. 1A).  
The expression level of ST2 mRNA along the adenoma-carcinoma sequence was also 
changed. As seen in Fig. 1B, the change in ST2 expression showed a pattern similar to that of 
IL-33 expression but to a more moderate degree. ST2 expression was greatly increased in the 
adenoma tissues but not changed in the CRC tissues compared to the normal controls (Fig. 
1B). 
The expression levels of IL-33/ST2 mRNA were analyzed against clinical pathological 
parameters in adenomas and sporadic CRCs 
Because the IL-33/ST2 axis has been reported to be involved in the pathogenesis of human 
cancers [21, 26, 33], the expression levels of IL-33/ST2 mRNA were analyzed against clinical 
pathological parameters of adenomas and CRCs.  
At the adenoma stage, the expression levels of both IL-33 and ST2 mRNAs were not 
correlated with degree of dysplasia (low grade dysplasia vs. moderate grade dysplasia vs. high 
grade dysplasia; IL-33: 6.74 ± 1.69 vs. 10.46 ± 2.65 vs. 11.71 ± 8.65; ST2: 2.56 ± 0.94 vs. 
4.09 ± 1.81 vs. 1.05 ± 0.35; both P >0.05 by the Kruskal–Wallis test). IL-33 and ST2 mRNA 
levels also did not differ between different histological subtypes/groups (tubular vs. 
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tubulovillous+villous; IL-33: 10.04 ± 2.33 vs. 6.99 ± 2.05; ST2: 3.40 ± 1.50 vs. 2.01 ± 0.34; 
both P >0.05 by the Mann–Whitney test).  
At the colorectal cancer stage, the expression level of IL-33 mRNA was not associated with 
TNM (tumor/node/metastasis) stage (TNM stage I + II vs. III+VI: 5.61 ± 2.00 vs. 4.89 ± 2.65: 
P >0.05 by the Mann–Whitney test) or node involvement (node negative vs. node positive: 
8.62 ± 2.85 vs. 8.01 ± 4.72, P >0.05 by the Mann–Whitney test). Similarly, the expression 
level of ST2 mRNA was not associated with node involvement (node negative vs. node 
positive: 2.03 ± 0.59 vs. 3.75 ± 1.09, P >0.05 by the Mann–Whitney test). However, the level 
of ST2 in CRC patients with advanced TNM stages was significantly higher than in those 
with early stages (TNM stage I + II vs. III+VI: 1.96 ± 0.66 vs. 3.59 ± 0.95: P <0.05 by the 
Mann–Whitney test).   
The significance of IL-33 and ST2 mRNA levels in predicating overall survival of patients 
with CRC  
Previous studies have shown that the expression level of IL-33/ST2 in certain types of human 
cancers might predicate the survival time [24, 26, 27].  Therefore, we analyzed the 
relationship between the expression levels of IL-33/ST2 and clinical prognosis in patients 
with sporadic CRC.  The overall survival data were available for 28 patients with CRC. 
Kaplan–Meier analysis revealed that both IL-33 level (Fig. 2A) and ST2 level (Fig. 2B) in 
cancer tissues were not associated with the overall survival in patients with CRC.  
Immunohistochemistry of IL-33 and ST2 distribution patterns in the tumor microenvironment 
of adenomas and CRCs  
Subsequently, we used IHC to examine the distribution patterns of IL-33 and its receptor, ST2, 
in the adenomatous and cancerous tumor microenvironments.  
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In the normal controls, IL-33 immunoreactivity was observed in the lamina propria but rarely 
in the epithelium (Fig. 3A). In adenomas and CRCs, IL-33 immunoreactivity was observed in 
both the tumor stroma and the epithelium. Many IL-33-positive cells were located in tumor-
associated microvessels (arrow in Fig. 3B & C) and in adenomatous and cancerous epithelium 
(arrow in Fig. 3B and inserted image in Fig. 3C). The semi-quantitative grading scores of IL-
33-positive cells in the adenomatous epithelium (Fig. 4A) and tumor stroma (Fig. 4B) were 
significantly higher than in the normal control; the grading scores of IL-33 in the CRC 
epithelium and tumor stroma were also higher than in the normal control, but lower than in 
the adenomatous epithelium and stroma (Fig. 4A & B).  
ST2 immunoreactivity was observed in both the epithelium and lamina propria in normal 
controls (Fig. 3D), adenomas (Fig. 3E) and CRCs (Fig. 3F). Notably, some of tumor-
associated microvessels in the adenoma/CRC tumor stroma (arrow in Fig. 3E for adenoma; 
arrow in Fig. 3E for CRC) were also positive for ST2 immunoreactivity. The semi-
quantitative grading score of ST2 immunoreactivity in the epithelium in all three groups was 
not significant different (see Fig. 4C). However, the grading score of ST2-positive stromal 
cells showed an increasing trend from the control to the adenoma stage and to the CRC stage 
(Fig. 4D). 
Because recent studies have demonstrated that vascular endothelial cells are one of the 
dominant IL-33-expressing cell populations [34], and because we observed an increased IL-
33 or ST2 positive microvessels in the tumor microenvironment, we quantified the IL-33-
positive microvessel density (MVD) and ST2-positive MVD in the adenoma and the CRC 
tumor stroma. The results revealed that both IL-33-positive MVD (Fig. 4E) and ST2-positive 
MVD (Fig. 4F) were significantly increased in the adenoma stroma and non-significantly 
increased in the CRC stroma compared to normal controls.  
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The phenotypic characterization of IL-33-positive cells in the tumor stroma  
To further identify the phenotypes of IL-33-positive cells in the tumor stroma, double IHC 
using IL-33/CD34 (to mark tumor-associated microvessels) and IL-33/SMA-alpha (to mark 
tumor-associated myofibroblasts) was performed. Compared to the control, the co-expression 
of IL-33 with CD34 (Fig. 5A-C) and SMA-alpha (Fig. 5D-F) in the stroma of 
adenomas/CRCs was frequently observed. This finding indicates that most IL-33-positive 





Accumulated evidence has suggested that inflammatory cytokines, including tumor necrosis 
factor (TNF)-α, IL-6 and IL-17A, are involved in the pathogenesis of the adenoma-
carcinoma transition [9, 13, 14, 35]. In this study, we found that the expression profile of the 
IL-33/ST2 axis within the tumor microenvironment was altered throughout the adenoma-
carcinoma sequence and might be involved in the process of CRC. In particular, IHC 
examination demonstrated that high IL-33/ST2 expression is likely to be partially produced 
by the tumor-associated microvessels, fueling an autocrine pathway involving IL-33/ST2 
expression and angiogenesis and ultimately influencing the development of colorectal 
adenomas and CRCs.  
IL-33 is a novel cytokine with a potential pro-inflammatory capacity. The importance of 
IL-33 in the development of the colorectal inflammatory disease ulcerative colitis has been 
addressed [18, 20]. Recent studies have also revealed that the elevation of IL-33 is involved 
in the pathogenesis of pancreatic cancer [23], gastric cancer [27] and liver cancer [25, 36], 
and ST2 is expressed in both the tumor cells and stromal cells [23]. However, there is very 
limited information available regarding the change in the IL-33/ST2 axis during the 
development of CRC.  To our best knowledge, the current study is the first of its kind to 
demonstrate a dynamic change in the IL-33/ST2 axis from colorectal adenomas to sporadic 
CRCs. The increase in IL-33 began at the adenoma stage and, although it declined slightly at 
the cancer stage compared to the adenoma stage, it was higher in both stages compared to 
controls. This finding might indicate that IL-33 is an early response inflammatory element 
and might serve as an alarm index for the colorectal neoplastic transformation. Although the 
exact mechanism for this expression pattern is currently unclear, it might be related to the 
changed expression patterns of IL-33 regulatory factors at different time periods during the 
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colorectal adenoma-carcinoma sequence. For instance, cytokines such as interferon (IFN)-γ 
and TNF-α are the well documented stimulators for IL-33 production [37-39], and we have 
previously demonstrated that the expression of IFN-gamma and TNF-α are remarkably 
elevated in adenoma tissues but reduced in CRC tissues [13]. This might partially explain the 
dynamic changes in IL-33 expression along the adenoma-carcinoma sequence. The 
expression of ST2 along the adenoma-carcinoma sequence was shown a pattern similar to 
that of IL-33; the expression level of ST2 mRNA was greatly increased at the adenoma stage 
but was unchanged from normal at the CRC stage. Taken together, our quantitative findings 
indicate that the greatest change in the IL-33/ST2 axis along the adenoma-carcinoma 
sequence occurred at the adenoma stage.  
With respect to the relationship between IL-33/ST2 and clinicopathological parameters of 
patients with adenomas and CRCs, we have found that although the difference did not reach 
statistical significance, the increased IL-33 expression in the adenoma tissues was associated 
with degree of dysplasia. Because the progression of dysplastic severity in adenomas is 
associated with a high malignant potential [40], our observation might imply that IL-33 is a 
potential stimulating factor for the disease stage progression. The expression level of ST2, 
but not IL-33, in the CRC tissues was associated with TNM stage; patients with advanced 
stages had a higher ST2 level than those with early stages. This finding is consist with the 
Jovanovic and colleagues’ data observed in breast cancer [33]  and suggests that ST2 could 
be an potential modulator in CRC progression by increasing binding avidity for IL-33. 
Previous publications have also reported that the expression level of IL-33/ST2 is related to 
survival in patients with certain types of cancer [24, 26, 27]. However, we could not confirm 
this relationship between the expression levels of IL-33/ST2 and survival in patients with 
sporadic CRC. The overall survival was not influenced by either IL-33 or ST2. However, 
given that the number of patients with CRC and survival data in this study was rather small 
 17 
(only 28 patients), it is necessary to investigate the prognostic significance of IL-33/ST2 in a 
large scale study of patients with CRC. 
The expression of IL-33 and the ST2 receptor has been studied in several types of 
digestive system cancers [23, 25, 27, 36] and has been found to be localized in various cell 
types within specific microenvironments [23]. Our IHC results clearly showed increased IL-
33 and ST2 immunoreactivity in the adenomatous/cancerous epithelium, supporting the 
possibility that the IL-33/ST2 axis is involved in regulating the transformation of colorectal 
epithelium. Our double IHC observations confirmed IL-33 immunoreactivity in 
myofibroblasts in the tumor stroma, which is consistent with previous findings from studies 
of patients with ulcerative colitis demonstrating that myofibroblasts are an important cellular 
source of IL-33 [18, 29, 41, 42]. In this study, our IHC observations of increased IL-33 
immunoreactivity in CD34-positive microvessels in the adenoma/CRC tumor stroma 
confirmed that vascular endothelial cells are the dominant IL-33-expressing cell population 
[34]. It has been recently reported that the pro-tumor mechanism of IL-33/ST2 is via 
enhanced angiogenesis in the mouse breast cancer model [33] and is mediated by its receptor, 
ST2, expressed in the effecting cells [19, 43]. In this study, we found that IL-33 was 
expressed in adenomatous/cancerous epithelium, tumor-associated myofibroblasts and 
microvessels and that ST2 was expressed in tumor-associated microvessels. By further 
quantifying IL-33-positive and ST2-positive MVDs, we found that both were significantly 
increased in adenoma/CRC tumor stroma. Our present findings might strongly support the 
hypothesis that increased expression of the IL-33/ST2 axis along the adenoma-carcinoma 
sequence enhances angiogenesis via paracrine and autocrine mechanisms. Because the 
expression of ST2 in adenomatous/cancerous epithelium has also been observed, a direct 
effect of IL-33 on transformed epithelial cells cannot be excluded, and further investigation is 
required.  
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In conclusion, our data reveal a dynamic change in the IL-33/ST2 axis along the 
colorectal adenoma-carcinoma sequence in which IL-33 and ST2 are more significantly 
increased at the adenoma stage than at the CTC stage. The expression levels of IL-33 and 
ST2 were not correlated with overall survival in patients with CRCs. Immunohistochemical 
identification of IL-33/ST2 phenotypes in adenoma/CRC might suggest a mixed cellular 
source in which tumor-associated microvessels are an important source of IL-33 and possess 
ST2 receptors in the tumor stroma; this might imply an autocrine mechanism of angiogenesis 
stimulation during the process of CRC. Additional studies are needed to further refine the 
exact functions and mechanisms of IL-33/ST2 contributing to the pathogenesis of adenomas 
and CRCs. 
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Table 1. Histological data of specimens from normal controls and patients with adenomas and 
colorectal cancer  
 
 Gender Pathology Dysplasia 
 male female tubular tubulovillous villous LGD MGD HGD 
Normal 20 10       
Adenoma 31 19 33 15 2 22 24 4 
      TNM stage 
   adenocarcinoma mucinous signet-ring I II III+IV 
Cancer 42 8 45 4 1 9 20 21 
 
LGD: lower grade dysplasia; MGD: moderate grade dysplasia; HGD: high grade dysplasia. 
 20 
Conflicts of interest 





1. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 
61:759-767 
2. Leslie A, Carey FA, Pratt NR, Steele RJ (2002) The colorectal adenoma-carcinoma 
sequence. Br J Surg 89:845-860 
3. Khosraviani K (1996) Colorectal adenoma-carcinoma sequence. Gut 39:342 
4. Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 
12:375-391 
5. Cacev T, Radosevic S, Krizanac S, Kapitanovic S (2008) Influence of interleukin-8 
and interleukin-10 on sporadic colon cancer development and progression. 
Carcinogenesis 29:1572-1580 
6. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 
14:6735-6741 
7. Fantini MC, Pallone F (2008) Cytokines: from gut inflammation to colorectal cancer. 
Curr Drug Targets 9:375-380 
8. Choi JW, Liu H, Shin DH, Yu GI, Hwang JS, Kim ES, Yun JW (2013) Proteomic and 
cytokine plasma biomarkers for predicting progression from colorectal adenoma to 
carcinoma in human patients. Proteomics 13:2361-2374 
9. Chung YC, Chang YF (2003) Significance of inflammatory cytokines in the 
progression of colorectal cancer. Hepatogastroenterology 50:1910-1913 
10. Kang M, Edmundson P, Araujo-Perez F, McCoy AN, Galanko J, Keku TO (2013) 
Association of plasma endotoxin, inflammatory cytokines and risk of colorectal 
adenomas. BMC cancer 13:91 
11. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, 
Sandler RS (2008) Circulating levels of inflammatory cytokines and risk of colorectal 
adenomas. Cancer Res 68:323-328 
12. Krzystek-Korpacka M, Diakowska D, Kapturkiewicz B, Bebenek M, Gamian A 
(2013) Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high 
cancer risk conditions, and health are distinct. Possible implications for CRC 
screening and surveillance. Cancer Lett 337:107-114 
13. Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, Florholmen J (2007) 
Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-
carcinomas sequence of colorectum. Cancer Immunol Immunother 56:985-995 
14. Cui G, Yuan A, Goll R, Vonen B, Florholmen J (2009) Dynamic changes of 
interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer 
Immunol Immunother 58:1897-1905 
15. Oliveira Frick V, Rubie C, Ghadjar P, Faust SK, Wagner M, Graber S, Schilling MK 
(2011) Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal 
malignancies. Tumour Biol 32:189-196 
16. Pellegrini P, Berghella AM, Contasta I, Del Beato T, Adorno D (2006) The study of a 
patient's immune system may prove to be a useful noninvasive tool for stage 
classification in colon cancer. Cancer Biother Radiopharm 21:443-467 
17. Liew FY (2012) IL-33: a Janus cytokine. Ann Rheum Dis 71 Suppl 2:i101-104 
18. Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, Lopez F, 
Gonzalez MJ, Quera R, Hermoso MA (2010) Characterization of the novel ST2/IL-33 
system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16:1097-
1107 
 22 
19. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic 
N, Lukic ML (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol 
Res 52:89-99 
20. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y, 
Andoh A (2010) Interleukin-33 expression is specifically enhanced in inflamed 
mucosa of ulcerative colitis. J Gastroenterol 45:999-1007 
21. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN, Lukic ML (2012) IL-
33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunology 1:229-231 
22. Eiwegger T, Akdis CA (2011) IL-33 links tissue cells, dendritic cells and Th2 cell 
development in a mouse model of asthma. Eur J Immunol 41:1535-1538 
23. Schmieder A, Multhoff G, Radons J (2012) Interleukin-33 acts as a pro-inflammatory 
cytokine and modulates its receptor gene expression in highly metastatic human 
pancreatic carcinoma cells. Cytokine 60:514-521 
24. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, Lin YS (2013) The paracrine 
effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness 
of head and neck squamous cell carcinoma. J Pathol 231:180-189 
25. Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, Yang DJ, Jiang YF (2012) 
Detection of interleukin-33 in serum and carcinoma tissue from patients with 
hepatocellular carcinoma and its clinical implications. J Int Med Res 40:1654-1661 
26. Hu LA, Fu Y, Zhang DN, Zhang J (2013) Serum IL-33 as a diagnostic and prognostic 
marker in non- small cell lung cancer. Asian Pac J Cancer Prev 14:2563-2566 
27. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y (2011) Serum interleukin-33 levels in 
patients with gastric cancer. Dig Dis Sci 56:3596-3601 
28. Musolino C, Allegra A, Profita M, Alonci A, Saitta S, Russo S, Bonanno A, Innao V, 
Gangemi S (2013) Reduced IL-33 plasma levels in multiple myeloma patients are 
associated with more advanced stage of disease. Br J Heamatol 160:709-710 
29. Seidelin JB, Rogler G, Nielsen OH (2011) A role for interleukin-33 in T(H)2-
polarized intestinal inflammation? Mucosal Immunol 4:496-502 
30. Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R (2006) Improvement 
of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression 
in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. 
Scand J Clin Lab Inv 66:249-259 
31. Cui G, Koh TJ, Chen D, Zhao CM, Takaishi S, Dockray GJ, Varro A, Rogers AB, Fox 
JG, Wang TC (2004) Overexpression of glycine-extended gastrin inhibits parietal cell 
loss and atrophy in the mouse stomach. Cancer Res 64:8160-8166 
32. Cui J, Xu G, Liu J, Pang Z, Florholmen J, Cui G (2013) The expression of non-mast 
histamine in tumor associated microvessels in human colorectal cancers. Pathol Oncol 
Res 19:311-316 
33. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, 
Arsenijevic NN, Lukic ML (2014) Interleukin-33/ST2 axis promotes breast cancer 
growth and metastases by facilitating intratumoral accumulation of 
immunosuppressive and innate lymphoid cells. Int J Cancer 134:1669-1682 
34. Kuchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, De 
Angelis PM, Scott H, Haraldsen G (2008) Nuclear interleukin-33 is generally 
expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory 
activation. Am J Pathol 173:1229-1242 
35. Contasta I, Berghella AM, Pellegrini P, Adorno D (2003) Passage from normal 
mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms 
regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 18:549-557 
 23 
36. Marvie P, Lisbonne M, L'Helgoualc'h A, Rauch M, Turlin B, Preisser L, Bourd-
Boittin K, Theret N, Gascan H, Piquet-Pellorce C, Samson M (2010) Interleukin-33 
overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 
14:1726-1739 
37. Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M (2012) Regulation of 
IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human 
epidermal keratinocytes. J Invest Dermatol 132:2593-2600 
38. Byrne SN, Beaugie C, O'Sullivan C, Leighton S, Halliday GM (2011) The immune-
modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin 
exposed to inflammatory UVB radiation. Am J Pathol 179:211-222 
39. Seltmann J, Werfel T, Wittmann M (2013) Evidence for a regulatory loop between 
IFN-gamma and IL-33 in skin inflammation. Exp Dermatol 22:102-107 
40. Gschwantler M, Kriwanek S, Langner E, Goritzer B, Schrutka-Kolbl C, Brownstone 
E, Feichtinger H, Weiss W (2002) High-grade dysplasia and invasive carcinoma in 
colorectal adenomas: a multivariate analysis of the impact of adenoma and patient 
characteristics. Eur J Gastroenterol Hepatol 14:183-188 
41. Ajdukovic J, Tonkic A, Salamunic I, Hozo I, Simunic M, Bonacin D (2010) 
Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. 
Hepatogastroenterology 57:1442-1444 
42. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH (2010) IL-33 
is upregulated in colonocytes of ulcerative colitis. Immunol Lett 128:80-85 
43. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM, Kwon YG 
(2009) Interleukin-33 induces angiogenesis and vascular permeability through 





Figure 1 legend 
 
Dynamic changes of IL-33 and ST2 transcripts along the colorectal adenoma-carcinoma 
sequence.  
The quantitative real-time PCR results showed that the expression of IL-33 mRNA was 
significantly increased to a ~9-fold higher level in adenoma tissues (grey bar in Fig. 1A); it 
was also higher in sporadic CRC tissues (black bar in Fig. 1A) than in normal controls (white 
bar in Fig. 1A), but significantly lower compared to the adenomas. The expression of ST2 
mRNA in adenoma tissues was increased to a ~3-fold higher level and slightly increased in 
CRC tissues compared to normal controls (Fig. 1B).  
 
(Y axes in Fig. 1A & B are fold changes relative to normal controls; P values are derived from 
the Mann-Whitney test) 
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Figure 2 legend 
Kaplan–Meier curves of overall survival differences among patients with sporadic CRC.  
The Kaplan–Meier analysis shows that the expression levels of IL-33 (Fig. 2A) and ST2 (Fig. 
2B) do not predicate the overall survival time in patients with sporadic CRC (both P values 
determined by the log-rank test).  
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Figure 3 legend 
Photograph presentations of IL-33 and its receptor, ST2, in the tumor stroma and the 
adenomatous/cancerous epithelium 
Immunohistochemical (IHC) results show that IL-33 immunoreactivity was not observed in 
the normal epithelium, and a low density of IL-33-positive cells was found in the lamina 
propria in the control (Fig. 3A). In both the adenoma and CRC, IL-33 immunoreactivity was 
frequently observed in tumor-associated microvessels (arrow in 3B & C) and 
adenomatous/cancerous epithelium (arrow in Fig. 3B for adenoma and inserted image in 3C 
for CRC). ST2 immunoreactivity was observed in both the epithelium (arrow head) and 
microvessels (arrow) in all three groups (Fig. 3D for control, 3E for adenoma and 3F for 
CRC).  
(A-E: IHC, counterstained with hematoxylin, original magnification 200×). 
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Figure 4 legend 
The density grading scores of IL-33 and ST2 positive cells in adenomas and CRC tissues 
The semi-quantitative results showed that the density of IL-33-positive cells in the 
adenomatous epithelium was higher than in the controls (gray bar in Fig. 4A). The density of 
IL-33-positive cells was also higher in the CRC epithelium (black bar in Fig. 4A) compared 
to the controls, but lower than the adenomatous epithelium (Fig. 4A). The density of IL-33-
positive stromal cells was increased in the adenoma stroma, with a smaller increase in 
magnitude of density in the CRC stroma (Fig. 4B). The density of ST2-positive cells in the 
adenomatous epithelium was non-statistically increased and was unchanged in the CRC 
cancerous epithelium (Fig. 4C). The density of ST2-positive cells in the stroma showed a 
gradually increasing trend from the control to adenoma to CRC, but these differences were 
not statistically significant (Fig. 4D). 
To examine the expression of IL-33/ST2 in endothelial cells, the number of IL-33-positive 
tumors associated with microvessel density (MVD) and the number of ST2-positive tumors 
associated with MVD were counted. The results show that the IL-33-positive MVD was 
significantly increased in the adenoma stroma and non-statistically increased in the CRC 
tumor stroma compared to normal lamina propria (Fig. 4E). The number of ST2-positive 
microvessels was greatly increased in both the adenoma stroma and the CRC tumor stroma 
compared to the normal lamina propria (Fig. 4F).     





Figure 5 legend 
The phenotypic characterization of IL-33-expressing cells in the adenoma and CRC tumor 
stromas  
Double IHC with IL-33/CD34 and IL-33/SMA-alpha revealed that an increase in IL-33-
positive cells (red) in the adenoma and CRC tumor stromas was frequently co-localized with 
CD34-labeled microvessels (blue) (Fig. 5B & C) and SMA-alpha labeled myofibroblasts 
(blue)  (Fig. 5E & F) compared to the normal lamina propria (Fig. 5A & D).   
 (A-F: double IHC, original magnification 400×; counterstaining was not applied) 
 
 
 
